Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Collection of Blood From Patients With Cancer

This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate.

Official registry: https://clinicaltrials.gov/study/NCT00034216 · National Cancer Institute (NCI) · enrollment listed as 1,750

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 1,750 people at Bethesda. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Biospecimen Acquisition From Human Subjects

Primary outcome (registry wording): Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis.

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Patients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible
  • Performance status of ECOG 0, 1, 2, or 3 for admission to this protocol
  • INCLUSION FOR APHERESIS:
  • Note: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference
  • Hemoglobin greater than or equal to 10 mg/dL and platelet count \> 75,000/mm(3)
  • Weight greater than 25 kg
  • Prothrombin Time - within normal limits

Public study contact (from the registry)

Michell J Manu, R.N.

(240) 529-3415

michell.manu@nih.gov

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Evaluation for NCI Surgery Branch Clinical Research Protocols

Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.

NCT00001823 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

FAQ about this NCT record

Is NCT00034216 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT00034216?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT00034216?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary